YH38560 / Yuhan Corp - LARVOL DELTA

YH38560, a novel bispecific fusion protein targeting 5T4 and CD47 in a tumor-selective manner for the treatment of solid cancers (SITC 2022) - "Correspondingly, YH38560 alone showed significant tumor growth inhibition superior to monospecific CD47 blockers and it exerted synergistic and durable anti-tumor effects when combined with either anti-PD-1 or PD-L1 Ab in MC38 syngeneic mouse model. Conclusions These findings suggest that YH38560 holds promising potential to improve patient outcomes over CD47-targeted therapies currently under development."

IO biomarker • Cervical Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD47 • SIRPA • TPBG